comprehensive care plans for chronic diseases in cardiology,
ophthalmology and metabolic disease. For example, in the case of a
metabolic disease like diabetes, the company is able to leverage its
strong positions in blood glucose monitoring, insulin delivery,
nutritionals and diagnostics as well as related areas like surgical
treatments for obesity and early-stage pharmaceuticals. Its
development of the Johnson & Johnson Diabetes Institute, LLC, (JJDI)
is one avenue for advancing professional education and patient
awareness about this disease's management. The JJDI, which has opened
facilities in Japan and the U.S., provides a powerful outlet for the
resources and experience Johnson & Johnson can harness in this area of
health care; additional facilities in Paris and Beijing are scheduled
to open later this year.
Science-based Innovation Anchors Consumer Health Care Success
In 2007, Johnson & Johnson's Consumer segment generated $14.5 billion dollars in sales. Its five major franchises -- OTC/Nutritionals; Skin Care; Baby Care; Women's Health and Oral Care -- feature some of the world's leading brands and compete in an estimated $480 billion global consumer products market.
The Consumer segment focuses on science-based innovations to drive the growth of its existing iconic brands, its development of new products and new ventures, and its expansion into emerging markets. Presentations on the Consumer segment address recent successes in the Skin Care franchise, the expansion of LISTERINE(R) and the Oral Care franchise, and the successful U.S. launch of over-the-counter Zyrtec(R).
Colleen Goggins, Worldwide Chairman of the Consumer Group says, "Our
vision, 'Bringing science to the art of healthy living,' reflects the
essence of how we create value and drive innovation." Goggins cites
critical strengths of the
'/>"/>
| SOURCE Johnson & Johnson Copyright©2008 PR Newswire. All rights reserved |